FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.
What happened
FDA inspected the Navi Mumbai plant from February 19 to 27, 2026 and found that environmental monitoring and other microbial samples were written into logbooks as collected and incubated, but the plates were missing and analysts confirmed the samples were never taken. Investigators also saw operators blocking sterile airflow over critical filling areas, damaged equipment inside aseptic areas, and cleaning with nonsterile wipes. The company agreed on June 19, 2026 to recall all sterile drug products, and FDA placed the firm's imports on Import Alert 66-40 (a list that lets FDA detain a firm's shipments) on July 9, 2026.
What FDA found
Microbial and environmental monitoring samples were recorded as collected and incubated even though the plates could not be found and analysts said the samples were never taken.
21 CFR 211.194(a)The lab computer system had no dilution factor, so batches were released on raw plate counts without evidence they met the microbial limit specifications.
21 CFR 211.194(a)Electronic leak-test reports were overwritten because files had no unique names, and no such integrity testing was done for one plant, so failed tests could not be traced.
21 CFR 211.194(a)Operators blocked first-air (the sterile airflow) over stopper bowls and vials during filling, and potentially compromised vials were not discarded.
21 CFR 211.113(b)Equipment inside aseptic areas was deteriorated or damaged, excess sealant sat near HEPA filters, nonsterile wipes were used, and standing water and staining were found nearby.
21 CFR 211.113(b)FDA found the quality unit was not enabled to use proper authority and the quality system was not effective.
What FDA wants
FDA asks the company to send a written response within 15 working days covering a full data integrity investigation, retrospective microbial review of U.S. batches, risk assessments, CAPA plans, independent consultant audits and quality unit remediation. The firm must also engage a qualified consultant under 21 CFR 211.34 to audit its whole operation before seeking resolution of its compliance status.
Who should pay attention
- hospitals, clinics and distributors that hold sterile drugs made at this site
- US companies that use Reliance Life Sciences as a contract manufacturer
- quality teams auditing suppliers in India for sterile product
This is a summary. Read the original letter on fda.gov.